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Abstract
Background: Recent evidence demonstrates that 14-3-3σ acts as a tumor suppressor gene
inactivated by methylation of its 5' CpG islands in epithelial tumor cells, while remaining un-
methylated in normal human epithelia. The methylation analysis of 14-3-3σ has been largely
overlooked in melanoma.
Methods: The methylation status of 14-3-3σ CpG island in melanocytes and melanoma cells was
analyzed by methylation-specific sequencing (MSS) and quantitative methylation-specific PCR (Q-
MSP). 14-3-3σ mRNA and protein expression in cell lines was detected by real-time RT-PCR and
western blot. Melanoma cells were also treated by 5-aza-2'-deoxycytidine (DAC), a demethylating
agent, and/or histone deacetylase inhibitor, Trichostatin A (TSA), to evaluate their effects on 14-3-
3σ gene expression.
Results: 14-3-3σ is hypermethylated in both human melanocytes and most melanoma cells in a
lineage-specific manner, resulting in the silencing of 14-3-3σ gene expression and the active
induction of 14-3-3σ mRNA and protein expression following treatment with DAC. We also
observed a synergistic effect upon gene expression when DAC was combined with TSA. The
promoter methylation status of 14-3-3σ was analyzed utilizing Q-MSP in 20 melanoma tissue
samples and 10 cell lines derived from these samples, showing that the majority of melanoma
samples maintain their hypermethylation status of the 14-3-3σ gene.
Conclusion: 14-3-3σ is hypermethylated in human melanoma in a cell-linage specific manner.
Spontaneous demethylation and re-expression of 14-3-3σ is a rare event in melanoma, indicating
14-3-3σ might have a tentative role in the pathogenesis of melanoma.
Background
14-3-3σ is a highly conserved acidic protein family, com-
posed of seven isoforms in mammals. Of the seven
known isoforms, 14-3-3σ appears to be the only one
directly involved in human cancer [1]. The 14-3-3σ gene
has been implicated in G2/M cell cycle arrest by p53 and
acts as a tumor suppressor gene (TSG) in colorectal cancer
[2]. 14-3-3σ (also know as Stratifin) was first identified as
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an epithelial cell antigen (HME-1) exclusively expressed
in human epithelia. Recent evidence demonstrates that
the 14-3-3σ gene promoter region is un-methylated in
normal epithelial cells while inactivated via hypermethyl-
ation of its 5' CpG islands in epithelial malignancies.
Gene silencing of 14-3-3σ by CpG hypermethylation has
been found to occur in many human cancer histologies,
including breast cancer [3], hepatocellular carcinoma [4],
vulvar squamous neoplasia [5], gastric carcinoma [6], oral
carcinoma [7], epithelial ovarian cancer [8], and prostate
and endometrial carcinoma [9].
The methylation status of 14-3-3σ in melanoma has not
been previously investigated. Thus, we wished to examine
whether 14-3-3σ gene is aberrantly methylated in
melanoma. We first examined the CpG island methyla-
tion status and gene expression of 14-3-3σ in normal
human epidermal melanocytes (NHEM) and melanoma
cells. We report that NHEM does not express significant
levels of 14-3-3σ protein, nor is it expressed at the tran-
scriptional level, primarily due to the dense hypermethyl-
ation of the 14-3-3σ gene CpG island. We show that the
14-3-3σ gene is methylated in most melanomas cells in a
cell lineage-specific manner, with spontaneous demethyl-
ation and re-expression of 14-3-3σ a rare event in human
melanoma.
Methods
Cell culture
The human melanoma cell lines, A375 (American Type
Culture Collection, Manassas, VA), WM266-4 (Wistar
Special Collection), Lox (established from a lymph node
metastasis of a patient at the Norwegian Radium Hospi-
tal) [10] and C8161.9 (a highly metastatic, amelanotic
melanoma cell line derived from an abdominal wall
metastasis) [11] were grown in monolayer culture in
RPMI 1640 with glutamine supplemented with 10% fetal
bovine serum at 37°C in a humidified atmosphere con-
sisting of 5% CO2 and 95% air. NHEM cell lines (Cam-
brex, Baltimore, MD) were cultured under the same
incubator conditions, utilizing specialized melanocyte
media (Cambrex) according to the supplier's recommen-
dations. We established numerous melanoma cell lines
from freshly excised clinical melanoma samples utilizing
previously published techniques for tissue procurement
and in vitro melanoma cell line growth and expansion
[12]. These melanoma cell lines were further characterized
by flow cytometry and/or cytospin preparation for cellular
confirmation of melanoma cell purity of >99% (data not
shown). All melanoma cell lines were derived from either
thick primary or metastatic melanoma tissue samples.
Tumor procurement
Over a 3-year period, we surgically procured tumor sam-
ples from patients with primary cutaneous melanoma
(PM) and metastatic melanoma (MM). All samples were
obtained under an Investigational Review Board (IRB)
approved tissue procurement protocol (MCC#13448,
IRB#101751; PSM# 990914-JM, 020318-JM). Upon surgi-
cal removal of the primary melanoma, a single surgical
oncologist (A.I.R.) utilized a scalpel to macrodissect and
procure a portion of the remaining primary tumor, with a
similar technique utilized for grossly involved lymph
nodes where the melanoma had completely replaced the
lymph node. Samples were taken from non-necrotic areas
of the tumor. The same process was performed for all dis-
tant metastases, careful to avoid surrounding tissues or
stroma. All samples were cryopreserved in liquid nitrogen
and stored within the Tissue Procurement Laboratory of
the Moffitt Cancer Center, securely de-identified through
a centralized database. We analyzed 4 thick PM's (>4 mm)
and 16 MM samples composed of 12 bulky, macroscopic
(replaced) lymph node metastases and 4 subcutaneous
metastases.
5-aza-2'-deoxycytidine and Trichostatin A treatment of 
cells
Melanoma cells were seeded at a density of 5 × 105 cells/
10 cm plate on day 1. Cell lines were treated with 5 μM
DAC (Sigma) for 96 hours or 200 ng/mL TSA (Sigma) for
24 hours. For the combination treatment, cells were first
treated with 5 μM DAC (Sigma) for 96 hours, then 200
ng/mL TSA were added and cells were treated for an addi-
tional 24 hours. Culture medium containing DAC or TSA
was prepared fresh daily. At the end of treatment, the
medium was removed and the RNA and protein were iso-
lated for subsequent reverse transcription PCR and West-
ern blot analysis.
Nucleic acid isolation and bisulfite modification
Genomic DNA (gDNA) was isolated from tumor tissue
and cultured cell lines, using Qiagen Blood and Cell Cul-
ture DNA Kit (Qiagen, Inc., Valencia, VA) and stored at -
20°C before use. 0.5 μg gDNA was used for bisulfite treat-
ment with the EZ DNA Methylation Kit (Zymo Research,
Orange, CA) according to the supplier's protocol.
Real-Time Quantitative Methylation-Specific PCR (Q-
MSP)
Promoter methylation of 14-3-3σ gene was investigated
utilizing quantitative, methylation-specific PCR (Q-MSP)
[13]. Briefly, bisulfite-treated DNA was amplified using
real-time PCR with oligonucleotide primers complemen-
tary to a region of the β-actin sequence that does not con-
tain CpG dinucleotides but does contain non-CpG
cytosines. From this, we were able to ascertain the amount
of converted input DNA template for each sample. Hyper-
methylation of 14-3-3σ CpG islands was then examined
with real-time PCR amplification of bisulfite-modified
DNA using oligonucleotide primers as reported [3]. TheBMC Cancer 2009, 9:162 http://www.biomedcentral.com/1471-2407/9/162
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performance of the Q-MSP primers was evaluated by run-
ning a standard curve and melting curve before they were
applied for quantitative gene methylation analysis in
tumor samples. All PCR reactions were carried out on an
iQ5 real-time thermal cycler (Bio-Rad, Hercules, CA) at
95°C for 10 min followed by 40 cycles of 95°C for 15 s
and 60°C for 60 s. Each PCR reaction was carried out in a
25 μl volume containing 2× SYBR Green PCR master mix
(Applied Biosystems, Foster City, CA), 200 nM each
primer and 1 μl bisulfite-modified gDNA. All reactions
were carried out in duplicate. Bisulfite-converted, univer-
sally methylated human gDNA (Chemicon, Temecula,
CA) and gDNA from MDA-MB-435 served as positive con-
trols and bisulfite-converted gDNA from MDA-MB-231
and blank reactions with water served as negative controls
as it has been shown that 14-3-3σ CpG island in MDA-
MB-231 cell line was un-methylated [3].
Methylation-specific sequencing (MSS) of 14-3-3σ CpG 
island
To further validate the MSP results, gDNA from NHEM
and C8161.9 was bisulfite- modified and the CpG island
in the first exon was amplified by PCR using the primers
as reported [3] which produce a PCR product with 474 bp
and containing 27 CpG dinucleotides. The PCR products
were gel purified using QIAquick Gel Extraction Kit (Qia-
gen, Valencia, CA, USA), ligated into pCR2.1-TOPO vec-
tors (Invitrogen) and transformed into DH5a-competent
cells (Invitrogen). 10 colonies were chosen randomly.
Plasmid DNA was purified and sequencing was carried
out by MWG Biotech, Inc. (Huntsville, AL).
RNA isolation and real-time reverse transcription PCR
Cultured normal melanocytes and melanoma cells lines
were collected and dissolved in TRIzol®  (Invitrogen,
Carlsbad, CA) and RNA was purified according to the
manufacturer's recommendations. Purified RNA was then
treated by DNase I (Roche, Indianapolis, IN) to remove
genomic DNA contamination. First-strand cDNA synthe-
sis was performed with 2 μg total RNA for each sample in
a total volume of 20 μl using a high capacity cDNA archive
kit (Applied Biosystems, Foster City, CA). The reverse
transcription reaction was performed with random prim-
ers and incubated at 25°C for 10 min followed by 37°C
for 120 min. Real-time PCR analysis of 14-3-3σ mRNA
was performed using Assays-on-Demand Gene Expression
Assays (Applied Biosystems, Foster City, CA) (assay ID:
Hs00602835_s1) with GAPDH (assay ID Hs9999
9905_m1) serving as an internal control. All PCR reac-
tions were performed in a total volume of 25 μl contain-
ing 2× TaqMan Universal PCR Master Mix (Applied
Biosystems), 20× Assays-on-Demand Gene Expression
Assay Mix and 40 ng cDNA. All assays were performed in
triplicate and run on an iQ5 real-time thermal cycler (Bio-
Rad, Hercules, CA) using the following conditions: 50°C
for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15
s and 60°C for 1 min. Relative quantitation of the ampli-
fied products was based upon Ct values.
Western blot analysis
Protein extracts were obtained from cell pellets utilizing
standard procedures, fractionated on a 12% polyacryla-
mide gel, transferred to a nitrocellulose membrane and
blocked for 1 h with 5% milk in Tris-buffered saline-T. 14-
3-3σ was detected using anti-14-3-3σ monoclonal mouse
antibody [1.N.6] (Abcam) in 5% milk in Tris-buffered
saline-T incubated overnight at 4°C. The immunoreactive
band (Mr 30 kDa) was visualized by the chemilumines-
cence kit (Immobilon Western; Millipore, Billerica, MA).
Beta-Actin was used as a control.
Results
14-3-3σ CpG island is hypermethylated in NHEM and 
most melanoma cell lines
We first utilized Q-MSP to determine the methylation sta-
tus of the 14-3-3σ gene in NHEM and several established
melanoma cell lines, including A375, C8161.9, LOX and
WM-266-4. Figure 1 shows a map of the CpG island for
the 14-3-3σ gene (662 bp) as well as the PCR primers uti-
lized for methylation analysis. As shown in Figure 2, con-
sistent with previous reports [3], the 14-3-3σ CpG island
was shown to be un-methylated in the cell line MDA-MB-
231, but heavily methylated in MDA-MB-435. This result
confirmed the accuracy of the Q-MSP method utilized
CpG island promoter region of the 14-3-3 gene Figure 1
CpG island promoter region of the 14-3-3 gene. The CpG Island Searcher Program (Takai et al, 2003) identified a CpG 
island within the 14-3-3σ gene, downstream of the transcriptional start site. Arrow represents the transcriptional start site. 
Blue line depicts the CpG island. Red line indicates the area analyzed by methylation-specific sequencing and black lines repre-
sent the location of the methylation specific PCR primers.BMC Cancer 2009, 9:162 http://www.biomedcentral.com/1471-2407/9/162
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here in evaluating 14-3-3σ CpG island methylation.
Results from Q-MSP reveal that the 14-3-3σ CpG island
was hypermethylated in NHEM as well as the melanoma
cell lines A375, LOX and WM266-4, but un-methylated in
C8161.9. To further validate the Q-MSP results, methyla-
tion-specific sequencing (MSS) was performed upon
genomic DNA derived from NHEM and C8161.9 cells.
Utilizing MSS, we evaluated the 27 CpG dinucleotides
contained within the CpG island of the first exon from the
14-3-3σ gene. Figure 3 shows that the MSS results are cor-
relative with the MSP results, demonstrating that all 27
CpG sites within the 14-3-3σ gene are heavily methylated
in NHEM but un-methylated in C8161.9.
Correlation of methylation status with 14-3-3σ gene 
expression
Expression of 14-3-3σ mRNA and protein were evaluated
with real-time RT-PCR and Western Blot analysis, respec-
tively. As shown in Figure 4, 14-3-3σ mRNA expression is
significant in C8161.9 but undetectable or very low in
NHEM and other melanoma cell lines. Western blot anal-
ysis shows that C8161.9 expressed the 14-3-3σ protein
while it was undetectable in NHEM. We did, however,
find a trace amount of protein in LOX (Figure 5). We sus-
pect that "leaking expression" from a few spontaneously
demethylated alleles within the 14-3-3σ gene may have
contributed to the protein expression. This expression pat-
tern is consistent with the 14-3-3σ gene methylation sta-
tus where only C8161.9 possessed an un-methylated CpG
island. The NHEM cells and remaining melanoma cell
lines harbored a hypermethylated CpG island within the
14-3-3σ gene.
Reversal of 14-3-3σ silencing following demethylation of 
CpG island
To further investigate whether CpG island methylation is
the principal mechanism leading to 14-3-3σ silencing in
NHEM and melanoma cell lines, we treated NHEM, LOX
and WM266-4 with the demethylating agent, 5-aza-2'-
deoxycytidine (DAC), alone or combined with the his-
tone deacetylase inhibitor (HDACi), Trichostatin A (TSA).
We then examined each cell line for evidence of re-expres-
Quantitative Methylation-Specific PCR analysis of 14-3-3σ  gene methylation level in cell lines Figure 2
Quantitative Methylation-Specific PCR analysis of 14-
3-3σ gene methylation level in cell lines. Error bars 
were defined as "mean +/- SD". M: universally methylated 
human genomic DNA as positive control.
Methylation-specific sequencing of 14-3-3σ DNA in cell lines  NHEM and C8161.9 Figure 3
Methylation-specific sequencing of 14-3-3σ DNA in 
cell lines NHEM and C8161.9. Open circles represent 
un-methylated CpG dinucleotides; filled circles represent 
methylated CpG dinucleotides. Nucleotide positions are rel-
ative to transcriptional start site.
Real-time PCR analysis of 14-3-3σ mRNA expression Figure 4
Real-time PCR analysis of 14-3-3σ mRNA expression. 
Error bars were defined as "mean +/- SD".BMC Cancer 2009, 9:162 http://www.biomedcentral.com/1471-2407/9/162
Page 5 of 7
(page number not for citation purposes)
sion of 14-3-3σ utilizing real-time RT-PCR and Western
blot analysis. We found that after treatment with DAC, 14-
3-3σ mRNA expression was significantly up-regulated in
NHEM (Figure 6a) as well as LOX and WM266-4 cell lines
(Figure 6b). TSA, used as a single agent, was unable to
induce 14-3-3σ mRNA re-expression, but was able to exert
a significant synergistic effect when combined with DAC
(Figure 6b). The Western blot results are correlative with
mRNA expression, as shown in Figure 7. Treatment of
C8161.9 with DAC alone or combined with TSA, which
possesses a fully un-methylated CpG island within the 14-
3-3σ gene, was not able to further induce 14-3-3σ mRNA
expressing (data not shown). Thus, our results suggest that
the hypermethylation of the CpG island in the 14-3-3σ
gene appears to be an active mechanism of gene silencing
in both NHEM and melanoma cells.
Hypermethylation status of the 14-3-3σ gene is 
maintained in melanoma samples
Our data demonstrates that the 14-3-3σ gene is hyper-
methylated in NHEM but hypomethylated in the highly
metastatic melanoma cell line C8161.9. We therefore
hypothesized that the hypermethylation status of 14-3-3σ
gene may be disrupted during melanoma progression as a
result of genome-wide hypomethylation, which is a
known characteristic of advanced-stage tumors [14]. We
next tested primary cell cultures of 10 daughter melanoma
cell lines originally derived from surgically procured
melanoma tissues for evidence of 14-3-3σ DNA methyla-
tion. Utilizing Q-MSP and real-time RT-PCR, we found no
detectable levels of 14-3-3σ mRNA expression within any
of the samples (0/10), with their CpG islands within the
14-3-3σ gene found to be highly hypermethylated. We
next analyzed 20 freshly procured and cryopreserved
melanoma tumor specimens from patients with stage III
and IV melanoma, where melanoma cells almost com-
pletely replaced the normal tissue (see Methods). We
found that all (20/20, 100%) samples exhibited signifi-
cant levels of 14-3-3σ DNA hypermethylation. These
results strongly demonstrate that most melanoma cells
maintain intrinsic levels of hypermethylation of the 14-3-
3σ gene, without concomitant levels of mRNA gene
expression. Thus, the spontaneous demethylation of 14-3-
3σ gene appears to be a relatively rare event in melanoma.
Western blot detection of 14-3-3σ protein in cell lines Figure 5
Western blot detection of 14-3-3σ protein in cell 
lines. Protein from MDA-MB-231 was utilized as positive 
control.
a. Real-time PCR analysis of 14-3-3σ mRNA expression in  DAC-treated NHEM Figure 6
a. Real-time PCR analysis of 14-3-3σ mRNA expres-
sion in DAC-treated NHEM. b. Real-time PCR analysis of 
14-3-3σ mRNA expression in DAC/TSA-treated melanoma 
cell lines LOX and WM266-4. Error bars were defined as 
"mean +/- SD".
Western blot detection of 14-3-3σ protein expression in  DAC/TSA-treated melanoma cell lines LOX and WM-266-4 Figure 7
Western blot detection of 14-3-3σ protein expression 
in DAC/TSA-treated melanoma cell lines LOX and 
WM-266-4.BMC Cancer 2009, 9:162 http://www.biomedcentral.com/1471-2407/9/162
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Discussion
We have attempted to identify hypermethylated genes in
melanoma, possibly serving as biomarkers and/or thera-
peutic targets for patients with advanced melanoma. The
14-3-3σ gene is notable because it has been shown to be
un-methylated in normal epithelial cells but aberrantly
methylated in several types of epithelial malignancies [3-
9] and was indicated as a tumor suppressor gene. In con-
trast to other histologic cancers, here we show that the 14-
3-3σ gene is hypermethylated in human melanoma in a
lineage-specific manner, as it is hypermethylated in both
NHEM and melanoma cells.
Several recent reports have indicated that cytosine methyl-
ation is an important event in the establishment and
maintenance of cell lineage-restricted gene expression
[15]. Such examples of genes that are methylated in nor-
mal cells in a lineage-specific manner are maspin [15] and
MAGE genes [16]. Previously, 14-3-3σ has been reported
to be hypermethylated in a cell-lineage-specific manner in
non-epithelial cells such as fibroblasts, lymphocytes,
chondrocytes and bone marrow [17]. Here, we report that
the 14-3-3σ gene is densely methylated in human epider-
mal melanocytes and most melanoma cells and that CpG
island hypermethylation results in the silencing of tran-
scription of the 14-3-3σ gene in both NHEM and
melanoma cells.
Transcription and expression of 14-3-3σ mRNA and pro-
tein are readily identified in the melanoma cell line
C8161.9, whose CpG island in 14-3-3σ is un-methylated.
At the same time, in those cell lines with a hypermethyl-
ated CpG island, DAC treatment results in the re-expres-
sion of 14-3-3σ. Significant synergistic effects are also
observed when DAC is combined with TSA, with TSA
treatment alone being unable to induce 14-3-3σ expres-
sion. These results strongly indicate that the 14-3-3σ gene
is hypermethylated and the chromatin is not accessible
due to hypoacetylated histones in NHEM and most
melanoma cells.
The 14-3-3σ gene is recognized as a negative cell cycle reg-
ulator that causes G2 arrest after DNA damage [18]. Lack
of 14-3-3σ gene expression may contribute to the malig-
nant transformation via the impairment of the G2 cell
cycle checkpoint function, allowing for the accumulation
of gene defects within the cell. The 14-3-3σ gene has also
been shown to be a regulator of mitotic translation
through its direct mitosis-specific binding to a variety of
translation/initiation factors [19]. The lack of 14-3-3σ
gene expression leads to aberrant mitotic translation and
the generation of binucleate cells. Aberrant silencing of
the 14-3-3σ gene in many types of epithelial malignancies
strongly suggests that it may function as a potent tumor
suppressor gene. Indeed, the tumor suppression effects of
14-3-3σ in melanoma have been examined in a model cell
line, MDA-MB-435. MDA-MB-435, originally thought to
represent a breast cancer cell line, was later confirmed to
be melanoma in origin [20]. Ferguson et al [18] demon-
strated that the over-expression of 14-3-3σ led to a rapid
and permanent G2 arrest in MDA-MB-435 cells. Thus re-
expression of 14-3-3σ in melanoma cells may be benefi-
cial for the control of melanoma growth, while further
investigation are required to determine the functional sig-
nificances of 14-3-3σ in melanoma.
Conclusion
Here, we show that 14-3-3σ/Stratifin, as an epithelial cell
antigen expressed in epithelia, is hypermethylated in both
human melanocytes and most melanoma cells in a line-
age-specific manner. This hypermethylation leads to
silencing of 14-3-3σ expression in human melanocytes
and melanoma cells. Spontaneous demethylation and re-
expression of 14-3-3σ is a rare event in melanoma.
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